SHR-2173 Injection/SHR-2173 placebo: Single dose SHR-2173 injection or matching placebo given subcutaneously
Study summary
The purpose of this study is to assess safety, PK, Pharmacodynamic and immunogenicity profile of a single dose of SHR-2173 in healthy participants
Eligibility
Sex
ALL
Min age
18 Years
Max age
45 Years
Healthy volunteers
Accepted
Main inclusion criteria
1. Healthy white participants.
2. Ability to understand the trial procedures and possible adverse events, volunteer to participate in the trial, and provide written informed consent, be able to comply with all the requirements, and able to complete the study.
3. Male aged between 18 to 45 years of age (inclusive)
4. Women with body weight ≥ 45.0 kg, men with body weight ≥ 50.0 kg, body mass index (BMI) between 19.0 and 30.0 kg/m2 (inclusive) at screening.
5. Men and WOCBP must agree to take highly effective contraceptive methods
Main exclusion Criteria
1. History or evidence of clinically significant disorders.
2. Individuals with a history of drug allergies, specific allergies, or known history or suspected of being allergic to the study or same class drug or any component of it.
3. Receipt of medical devices or another investigational drug within 3 months or 5 half-lives, whichever is longer prior to screening.
4. The injection site has abnormalities or is deemed by the investigator as unsuitable for subcutaneous injection.
5. History of excessive smoking in the past 1 month prior to screening
6. History of illicit or prescription drug abuse or addiction within 1 year of screening, or positive urine drug screen at baseline.
7. Any other circumstances (e.g., not suitable for venous access) or laboratory abnormality that, in the investigator's judgment, may increase the risk to the participant, or be associated with the participant's participation in and completion of the study or could preclude the evaluation of the participant's response.
NOTE: Other protocol defined Inclusion/Exclusion criteria may apply
Primary outcome measure(s)
Pharmacokinetics - Cmax — Day 71 Maximum observed plasma concentration (Cmax)
Pharmacokinetics - AUC₀-t — Day 71 Area under the plasma concentration-time curve from time 0 to the last measurable concentration (AUC₀-t)
Pharmacokinetics - AUC₀-inf — Day 71 Area under the plasma concentration-time curve from time 0 extrapolated to infinity (AUC₀-inf)
Pharmacokinetics - Tmax — Day 71 Time to reach maximum observed plasma concentration (Tmax)
Pharmacokinetics - t½ — Day 71 Terminal elimination half-life (t½)
Immunogenicity - Anti-Drug Antibody (ADA) — Day 71 Incidence and onset time of anti-drug antibody (ADA)
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.